Biotechnology
ILIAS Biologics Inc. demonstrated the therapeutic effect of anti-inflammatory exosomes for ischemia-reperfusion-induced acute kidney injury
DAEJEON, South Korea, June 28, 2021 /PRNewswire/ -- Anti-inflammatory exosomes could have a place in treating acute kidney injury (AKI) caused by ischemia repercussion injury (IRI), according to a study done by ILIAS Biologics, Inc. in collaboration withYonsei University of Seoul, South Korea. ...
2021-06-28 20:00
2009
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study
Opaganib strongly inhibits Beta (South African) and Gamma (Brazilian) COVID-19 variants, further supporting its antiviral activity Opaganib's unique, orally-administered, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is also expected to maintain effect agai...
2021-06-28 19:00
12979
InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL
BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the trea...
2021-06-28 16:02
11010
Qbiotics concludes successful $85 million capital raise
* Capital raise nets $85 million from Existing Shareholders, Existing Institutional Investors, and cornerstone investor TDM Growth Partners. * Funding to enable human clinical development of the Company's anticancer drug candidate tigilanol tiglate and its wound healing drug candidate EBC-1013...
2021-06-28 09:36
3500
CStone announces positive registrational study of GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer
* Key efficacy data for GAVRETO showed deep and durable anti-tumor activity in Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) * In March 2021, GAVRETO was approved by the National Medical Products Administration (NMPA) ofChina for the treatment of patie...
2021-06-28 08:05
6698
BIO Asia-Taiwan 2021 to Go Ahead in 'All Online' Format
TAIPEI, June 28, 2021 /PRNewswire/ -- In response to ongoing restrictions in Taiwan due to the COVID-19 pandemic, BIO Asia-Taiwan 2021 will be held as scheduled fromJuly 21-25 but in an all-online format, with activities including the Conference, Exhibition, BIO's One-on-one Partnering™, Company ...
2021-06-28 07:30
2726
Sanyou Biopharmaceuticals completes series B financing and secures its leading role in innovative antibody drug discovery
SHANGHAI, June 26, 2021 /PRNewswire/ -- Sanyou Biopharmaceutical (Shanghai) Co., Ltd. (hereafter referred to as "Sanyou Bio" or "the Company"), a leading company in innovative antibody drug discovery, announced the closing of series B financing. This financing round was co-led by LH Ventures and ...
2021-06-26 23:00
4244
World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years
* Independent modelling estimates the PromarkerD predictive test for diabetic kidney disease (DKD) would increase the quality of care and could save US payers almostUSD400 billion over 10 years * The US is home to 31 million adults with diabetes who are at risk of DKD - cost savings stem from...
2021-06-25 23:30
3160
Vazyme Brings COVID-19 Testing Solutions at Medlab 2021
DUBAI, UAE, June 25, 2021 /PRNewswire/ -- Chinese biotechnology company Nanjing Vazyme Biotech Co., Ltd (Vazyme) showcased its lineup of COVID-19 testing solutions and its point-of-care testing (POCT) in vitro diagnostic instruments at the 2021 Medlab Middle East, an industry-leading medical labo...
2021-06-25 15:31
1949
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003
HANGZHOU, China, June 25, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative drug development company, announced today that its new Class I innovative drug LNK01003, has been approved by National Medical Products Administration (...
2021-06-25 15:11
5448
Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer
SHANGHAI, June 25, 2021 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today one study in collaboration with Ruijin Hospital, Shanghai Jiaotong ...
2021-06-25 15:06
1907
GenScript receives "Best Contract Development and Manufacturing Organization Award" in the Korea Bioprocessing Excellence Awards 2021
SINGAPORE, June 25, 2021 /PRNewswire/ -- GenScript receives the "Best Contract
Development and Manufacturing Organization Award" on the Korea Bioprocessing
Excellence Awards 2021 held on 24th June 2021. GenScript achieve the Best CDMO
award for two years in a row.
2021-06-25 10:30
19346
Samsung Biologics Issues Its First Annual Sustainability Report
* Consolidation of the company's roadmap to creating an improved business environment * Establishment of an ESG Committee for its continued efforts for environmental performance * Showcases the company's long-term commitment to social responsibility as part of its mission to build a bett...
2021-06-25 09:01
23316
TCI JAPAN Launched its Breakthrough, SCIENCE OF PROBIOTICS, Demonstrating How to Keep Probiotics Alive without Refrigeration for over 1 year
TAIPEI, June 24, 2021 /PRNewswire/ -- To keep enough probiotics alive in products, sellers and consumers must meet the storage conditions, especially storagetemperature. Since most live probiotics can only survive in a low-temperature environment, most probiotic products, especially lactic acid ...
2021-06-25 09:00
2521
Moving ahead: Copan announces a major rebranding and launches a new website
BRESCIA, Italy, June 25, 2021 /PRNewswire/ -- Time of change for Copan. The Italian preanalytics company announced the completion of an extensive rebranding initiative which includes a new logo and a new website with updated functionalities. The rebranding aims to represent at best the company va...
2021-06-25 08:25
3753
Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Glucagon-like Peptide-1 and Glucagon Receptor Dual Agonist in Overweight or Obese Chinese Participants at the American Diabetes Association's 81st Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-06-25 08:00
7348
Bridge Biotherapeutics Integrates CDD Vault Collaborative Database Solution into Its R&D Platform to Harmonize Research and Drug Discovery Project Management
- Bridge has been enhancing its research and drug discovery engines by efficiently managing scientific assets on a collaborative database solution - CDD provides a secure research database platform enabling seamless collaboration between drug discovery and development teams that are in different...
2021-06-25 05:57
2713
GenesisCare Expands their MR-guided Radiotherapy Reach with the Purchase of Multiple MRIdian® Systems
Master agreement includes program plans for up to a further 14 systems with immediate expansion in 2 key markets CLEVELAND, June 24, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that GenesisCare has entered into a master purchase agreement for up to 14 MRIdian® MR-Guided The...
2021-06-24 22:33
14790
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan
SHENZHEN, China, June 24, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Tucidinostat (also known as Chidamide, Epidaza ®, HBI-8000) monotherapy of relapsed or refractory (R/R) adult T-cell le...
2021-06-24 19:00
3857
Over a year into the global pandemic, Samsung Biologics continues to leverage innovative virtual platform for remote audits and regulatory inspections
* Samsung Biologics' Live Virtual Tour (LVT) used in one of the earliest FDA full virtual assessments * Recently hosted EMA for 6 PAIs simultaneously using LVT INCHEON, South Korea ,June 23, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (C...
2021-06-23 19:28
1945
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
5774
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
5771
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
5708
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
5578
